| |
New investments in health tech have set the stage for industry players and revolutionary AI in imaging, drug discovery, digital therapeutics, and more.
Download our whitepaper for trends industry experts believe will shape the virtual care landscape. 
|
|
Today’s Big NewsSep 28, 2023 |
| By Max Bayer FDA advisers voted down BrainStorm's cell therapy for ALS, saying that there was not enough evidence to demonstrate the treatment's potential efficacy. The committee also raised issues with the lack of data on the company's manufacturing and delivery process. |
|
|
|
By Conor Hale Though slowdowns in medical procedures, elective surgeries and clinic visits were felt across the medtech industry, the new data provide a clear look into the effects of the spreading coronavirus on cancer pathology work during the first months of 2020. |
By Kevin Dunleavy Slated for an FDA decision last October, Amicus Therapeutics’ Pompe disease bid was foiled by COVID-related travel restrictions. Nearly a year later, the Philadelphia company has gained its long-awaited green light. |
By Angus Liu Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now. 
|
|
By Zoey Becker As some cancer centers struggle to secure access to key platinum-based chemotherapies, a national spotlight gives the issue newfound political importance. But will this be a turning point for the recurrent shortage issue? ASCO's Julie Gralow, M.D., certainly hopes so. |
By Andrea Park Something big is looming in Harbinger Health’s future, and the company has now secured a sizable funding round to help get it there. |
By Max Bayer Karuna has formally submitted a new drug application to the FDA for its schizophrenia treatment. The company expects to launch in the second half of 2024 if approved. |
By Andrea Park Base editing has been lauded as a potential “game changer” for a broad swath of diseases, and Revvity is aiming to help usher in that change. |
By Nick Paul Taylor Healthcare professionals don’t trust your digital content. That is the stark conclusion of a survey of HCPs, which found 80% of consultants are skeptical of pharma content because of doubts about the cherry-picking of data and other concerns. |
By Nick Paul Taylor Bionomics’ bid to bounce back from its stock-crushing anxiety trial failure has gained a little momentum, with investors sending the share price up over 180% on the strength of phase 2 data in post-traumatic stress disorder. |
By Conor Hale Working in collaboration with researchers from Fukushima Medical University in Japan, the outfit plans to develop protein microarray technology capable of sifting through the tens of thousands of proteins found within blood samples. |
By Fraiser Kansteiner A court in Germany suspended infringement proceedings on four patents at issue in the lawsuit filed by CureVac against BioNTech. Still, CureVac said there's reason to be optimistic its arguments may win out. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," Heather Landi from Fierce Healthcare engages in a conversation with Othman Laraki, co-founder and CEO of Color Health. They delve into strategies for boosting screenings and explore the partnership between Color Health and the American Cancer Society, aimed at making convenient cancer screenings more accessible. |
|
|---|
|
|
|
Thursday, October 5, 2023 | 11am ET / 8am PT Viral vectors used in gene therapies face complex and multifaceted analytical challenges. Developing standardized and validated analytical methods, reference standards, and reagents are critical to overcoming these challenges. Join us to learn how to accelerate the development and translation of safe and effective viral vector-based gene therapies with next-generation analytics. Register now. .png)
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
